1 Table of Contents 1 Table of Contents 4 1.1 List of Tables 6 1.2 List of Figures 7 2 Introduction 10 2.1 Disease Cluster Introduction 10 2.2 Symptoms 11 2.2.1 Pneumonia 11 2.2.2 MRSA 11 2.2.3 Sepsis 11 2.2.4 Tuberculosis 11 2.3 Diagnosis 12 2.3.1 Pneumonia 12 2.3.2 MRSA 12 2.3.3 Sepsis 12 2.3.4 Tuberculosis 12 2.4 Etiology and Pathophysiology 13 2.4.1 Pneumonia 13 2.4.2 MRSA 14 2.4.3 Sepsis 15 2.4.4 Tuberculosis 15 2.5 Epidemiology 16 2.5.1 Pneumonia 16 2.5.2 MRSA 17 2.5.3 Sepsis 17 2.5.4 Tuberculosis 18 2.6 Comorbidities and Complications 18 2.6.1 Pneumonia 19 2.6.2 MRSA 19 2.6.3 Sepsis 19 2.6.4 Tuberculosis 19 2.7 Prognosis 19 2.7.1 Pneumonia 19 2.7.2 MRSA 20 2.7.3 Sepsis 20 2.7.4 Tuberculosis 20 2.8 Treatment 20 2.8.1 Beta-lactams 21 2.8.2 Protein Synthesis inhibitors 22 2.8.3 Vaccines 23 2.8.4 Other Classes of Antibacterial Therapy 23 3 Key Marketed Products 24 3.1 Overview 24 3.2 Cubicin (daptomycin) – Merck & Co 25 3.3 Augmentin – GlaxoSmithKline 27 3.4 Prevnar 13 – Pfizer 29 3.5 Infanrix – GlaxoSmithKline 30 3.6 Boostrix – GlaxoSmithKline 32 3.7 Zerbaxa – Merck and Co 33 3.8 Bexsero – GlaxoSmithKline 35 3.9 Zyvox – Pfizer 36 3.10 Conclusion 38 4 Pipeline Landscape Assessment 39 4.1 Overview 39 4.2 Pipeline Development Landscape 39 4.3 Mechanisms of Action in Pipeline 42 4.4 Clinical Trial Landscape 45 4.4.1 Failure Rate by Stage of Development, Indication and Molecule Type 46 4.4.2 Clinical Trial Duration by Stage of Development, Indication, and Molecule Type 50 4.4.3 Clinical Trial Size by Stage of Development, Indication and Molecule Type 53 4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication and Molecule Type 57 4.5 Conclusion 61 4.6 Assessment of Key Pipeline Products 61 4.6.1 Solithera – Cempra 61 4.6.2 Arikace – Insmed 62 4.6.3 Cadazolid – Actelion 63 4.6.4 Plazomicin (plazomicin sulfate) – Achaogen 64 4.6.5 V114 – Merck & Co. 65 4.6.6 Suvratoxumab (MEDI4893) – MedImmune 66 4.6.7 Pf-06290510 (SA4Ag vaccine) – Pfizer 67 4.6.8 PF-06425090 – Pfizer 68 4.6.9 Conclusion 69 5 Multi-Scenario Market Forecast to 2022 70 5.1 Overall Market Size 70 5.2 Generic Penetration 73 5.3 Revenue Forecast by Mechanism of Action 75 5.3.1 Immune Response 75 5.3.2 Bacterial Cell Wall Disruptor/Inhibitor 76 5.3.3 Protein Synthesis Inhibitors 77 5.3.4 DNA Inhibitors 78 5.3.5 Multiple Mechanisms of Action 79 6 Company Analysis and Positioning 80 6.1 Revenue and Market Share Analysis by Company 81 6.1.1 Pfizer – Will it Maintain its Position as Market Leader? 85 6.1.2 GlaxoSmithKline – Will Revenues for Key Products Continue to Grow Over Forecast Period? 86 6.1.3 Merck & Co – How Will Key Approvals and Patent Expiries Affect Revenue? 87 6.1.4 Allergan – Revenues to Rise Rapidly Following Market Entry 88 6.1.5 Cempra – Set to Enter the Market in 2017 89 6.1.6 Insmed – Set to Enter the Market in 2018 90 6.1.7 Otsuka – How Will the Approval of Deltyba Affect Otsuka’s Market Share? 91 6.1.8 Roche – Revenues to Continue to Decline Due to Lack of Pipeline Products 92 6.1.9 Bayer – Steady Decline as All Products Off-Patent 93 6.1.10 AstraZeneca – Set to Revitalize its Position within the Market 94 6.2 Company Landscape 95 6.3 Marketed and Pipeline Portfolio Analysis 96 7 Strategic Consolidations 99 7.1 Licensing Deals 99 7.1.1 Deals by Region, Value and Year 99 7.1.2 Deals by Indication 100 7.1.3 Deals by Stage of Development and Value 101 7.1.4 Deals by Molecule Type, Mechanism of Action and Value 103 7.1.5 Licensing Deals Valued Above $100m 104 7.2 Co-development Deals 105 7.2.1 Deals by Region, Value and Year 105 7.2.2 Deals by Indication 107 7.2.3 Deals by Stage of Development and Value 107 7.2.4 Deals by Molecule Type and Value 109 7.2.5 Co-development Deals Valued Above $100m 109 8 Appendix 111 8.1 References 111 8.2 Table of all Pipeline Products 115 8.3 Table of Epidemiology Forecast 171 8.4 Abbreviations 173 8.5 Methodology 175 8.5.1 Coverage 175 8.5.2 Secondary Research 175 8.5.3 Market Size and Revenue Forecasts 175 8.5.4 Pipeline Analysis 176 8.5.5 Competitive Landscape 176 8.6 Contact Us 177 8.7 Disclaimer 177

1.1 List of Tables Table 1: Antibacterial Drug Market, Global, Key Marketed Products and Approved Indications, 2016 25 Table 2: Antibacterial Drug Market, Global, Approved Indications for Cubicin, 2016 26 Table 3: Antibacterial Drug Market, Global, Approved Indications for Augmentin, 2016 27 Table 4: Antibacterial Drug Market, Global, Approved Indications for Prevnar 13, 2016 29 Table 5: Antibacterial Drug Market, Global, Approved Indications for Infanrix, 2016 30 Table 6: Antibacterial Drug Market, Global, Approved Indications for Boostrix, 2016 32 Table 7: Antibacterial Drug Market, Global, Approved Indications for Zerbaxa, 2016 33 Table 8: Antibacterial Drug Market, Global, Approved Indications for Bexsero, 2016 35 Table 9: Antibacterial Drug Market, Global, Approved Indications for Zyvox, 2016 36 Table 10: Antibacterial Drug Market, Global, Annual Revenue Forecast for Key Products ($m), 2015–2022 72 Table 11: Antibacterial Drug Market, Global, Usage of Generics Across Key Indications, 2015 75 Table 12: Antibacterial Drug Market, Global, Forecast Revenues by Company, 2015–2022 82 Table 13: Antibacterial Drug Market, Global, Licensing Deals Valued Above $100m, 2006–2016 104 Table 14: Antibacterial Drug Market, Global, Co-development Deals Above $100m, 2006–2016 110 Table 15: Antibacterial Drug Market, Global, Pipeline Products, Discovery, 2016 115 Table 16: Antibacterial Drug Market, Global, Pipeline Products, Preclinical, 2016 133 Table 17: Antibacterial Drug Market, Global, Pipeline Products, IND/CTA-filed, 2016 158 Table 18: Antibacterial Drug Market, Global, Pipeline Products, Phase I, 2016 159 Table 19: Antibacterial Drug Market, Global, Pipeline Products, Phase II, 2016 163 Table 20: Antibacterial Drug Market, Global, Pipeline Products, Phase III, 2016 167 Table 21: Antibacterial Drug Market, Global, Pipeline Products,Pre-registration, 2016 170 Table 22: Antibacterial Drug Market, Global, Pipeline Products, Unknown, 2016 170 Table 23: Antibacterial Drug Market, Prevalence Patterns for Pneumonia, 2015–2022 171 Table 24: Antibacterial Drug Market, Vaccinations Patterns for Pneumonia, 2015–2022 171 Table 25: Antibacterial Drug Market, Prevalence Patterns for Sepsis, 2015–2022 172 Table 26: Antibacterial Drug Market, Prevalence Patterns for Tuberculosis, 2015–2022 172 Table 27: Abbreviations 1731.2 List of Figures Figure 1: Antibacterial Drug Market, Global, Epidemiology Patterns for Pneumonia Incidence, 2015–2022 16 Figure 2: Antibacterial Drug Market, Global, Epidemiology Patterns for Pneumococcal Vaccinations, 2015–2022 17 Figure 3: Antibacterial Drug Market, Global, Epidemiology Patterns for Sepsis, 2015–2022 18 Figure 4: Antibacterial Drug Market, Global, Epidemiology Patterns for Tuberculosis, 2015–2022 18 Figure 5: Antibacterial Drug Market, Global, Annual Revenue for Cubicin ($m), 2006–2022 27 Figure 6: Antibacterial Drug Market, Global, Annual Revenue for Augmentin ($m), 2006–2022 28 Figure 7: Antibacterial Drug Market, Global, Annual Revenue for Prevnar 13 ($bn), 2009–2022 30 Figure 8: Antibacterial Drug Market, Global, Annual Revenue for Infanrix ($bn), 2006–2022 31 Figure 9: Antibacterial Drug Market, Global, Annual Revenue for Boostrix ($m), 2006–2022 33 Figure 10: Antibacterial Drug Market, Global, Annual Revenue for Zerbaxa ($m), 2016–2022 34 Figure 11: Antibacterial Drug Market, Global, Annual Revenue for Bexsero ($m), 2015–2022 36 Figure 12: Antibacterial Drug Market, Global, Annual Revenue for Zyvox ($bn), 2006–2022 37 Figure 13: Antibacterial Drug Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016 39 Figure 14: Antibacterial Drug Market, Global, Pipeline by Stage of Development and Molecule Type, 2016 40 Figure 15: Antibacterial Drug Market, Global, Pipeline, Key Indications by Stage of Development, 2016 41 Figure 16: Antibacterial Drug Market, Global, Pipeline, Key Indications Molecule Type, 2016 42 Figure 17: Antibacterial Drug Market, Global, Overall Pipeline by Mechanism of Action, 2016 43 Figure 18: Antibacterial Drug Market, Global, Pipeline by Mechanism of Action and Stage of Development, 2016 44 Figure 19: Antibacterial Drug Market, Global, Pipeline for Key Bacterial Indications by Mechanism of Action, 2016 45 Figure 20: Antibacterial Drug Market, Global, Clinical Trial Failure Rates by Stage of Development (%), 2006–2016 46 Figure 21: Antibacterial Drug Market, Global, Clinical Trial Failure Rates by Stage of Development and Indication (%), 2006–2016 47 Figure 22: Antibacterial Drug Market, Global, Clinical Trial Failure Rates by Stage of Development and Molecule Type (%), 2006–2016 48 Figure 23: Antibacterial Drug Market, Global, Clinical Trial Failure Rates by Stage of Development and Mechanism of Action (%), 2006–2016 49 Figure 24: Antibacterial Drug Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2016 50 Figure 25: Antibacterial Drug Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2016 51 Figure 26: Antibacterial Drug Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2016 52 Figure 27: Antibacterial Drug Market, Global, Clinical Trial Duration by Stage of Development and Mechanism of Action (months), 2006–2016 53 Figure 28: Antibacterial Drug Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2016 54 Figure 29: Antibacterial Drug Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2016 54 Figure 30: Antibacterial Drug Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2016 55 Figure 31: Antibacterial Drug Market, Global, Clinical Trial Size by Stage of Development and Mechanism of Action (participants), 2006–2016 56 Figure 32: Antibacterial Drug Market, Global, Aggregate Clinical Program Size by Stage of Development (participants), 2006–2016 57 Figure 33: Antibacterial Drug Market, Global, Aggregate Clinical Program Size by Stage of Development and Indication (participants), 2006–2016 58 Figure 34: Antibacterial Drug Market, Global, Aggregate Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2016 59 Figure 35: Antibacterial Drug Market, Global, Aggregate Clinical Program Size by Stage of Development and Mechansim of Action(participants), 2006–2016 60 Figure 36: Antibacterial Drug Market, Global, Revenue Forecast for Solithera ($m), 2017–2022 62 Figure 37: Antibacterial Drug Market, Global, Revenue Forecast for Arikace ($m), 2018–2022 63 Figure 38: Antibacterial Drug Market, Global, Revenue Forecast for Cadazolid ($m), 2017–2022 64 Figure 39: Antibacterial Drugs Market, Global, Revenue Forecast for Plazomicin ($m), 2018–2022 65 Figure 40: Antibacterial Drug Market, Global, Revenue Forecast for V114 ($m), 2019–2022 66 Figure 41: Antibacterial Drugs Market, Global, Revenue Forecast for MEDI4893 ($m), 2019–2022 67 Figure 42: Antibacterial Drugs Market, Global, Revenue Forecast for Pf-06290510 ($m), 2018–2022 68 Figure 43: Antibacterial Drugs Market, Global, Revenue Forecast for Pf-06425090 ($m), 2018–2022 69 Figure 44: Antibacterial Drug Market, Global, Market Size ($bn), 2015–2022 71 Figure 45: Antibacterial Drug Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2015–2022 74 Figure 46: Antibacterial Drug Market, Global, Annual Revenue Forecast for Drugs That Modify the Immune Response ($bn), 2015–2022 76 Figure 47: Antibacterial Drug Market, Global, Annual Revenue Forecast for Bacterial Cell Wall Disruptors/Inhibitors ($bn), 2015–2022 77 Figure 48: Antibacterial Drug Market, Global, Annual Revenue Forecast for Protein Synthesis Inhibitors ($bn), 2015–2022 78 Figure 49: Antibacterial Drug Market, Global, Annual Revenue Forecast for DNA Inhibitors ($bn), 2015–2022 78 Figure 50: Antibacterial Drug Market, Global, Annual Revenue Forecast for Drugs With Multiple Mechanisms of Action ($bn), 2015–2022 79 Figure 51: Antibacterial Drug Market, Global, Cluster by Growth and Market Share, 2015–2022 80 Figure 52: Antibacterial Drug Market, Global, Company Analysis Matrix, 2016 81 Figure 53: Antibacterial Drug Market, Global, Forecast Market Share by Company (%), 2015–2022 83 Figure 54: Antibacterial Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2015–2022 84 Figure 55: Antibacterial Drug Market, Global, Revenues by Product Type, 2015–2022 85 Figure 56: Antibacterial Drug Market, Global, Pfizer Annual Revenue Forecast, 2015–2022 86 Figure 57: Antibacterial Drug Market, Global, GlaxoSmithKline Annual Revenue Forecast, 2015–2022 87 Figure 58: Antibacterial Drug Market, Global, Merck & Co Annual Revenue Forecast, 2015–2022 88 Figure 59: Antibacterial Drug Market, Global, Allergan Annual Revenue Forecast, 2015–2022 89 Figure 60: Antibacterial Drug Market, Global, Cempra Annual Revenue Forecast, 2015–2022 90 Figure 61: Antibacterial Drug Market, Global, Insmed Annual Revenue Forecast, 2015–2022 91 Figure 62: Antibacterial Drug Market, Global, Otsuka Annual Revenue Forecast, 2015–2022 92 Figure 63: Antibacterial Drug Market, Global, Roche Annual Revenue Forecast, 2015–2022 93 Figure 64: Antibacterial Drug Market, Global, Bayer Annual Revenue Forecast, 2015–2022 94 Figure 65: Antibacterial Drug Market, Global, AstraZeneca Annual Revenue Forecast, 2015–2022 95 Figure 66: Antibacterial Drug Market, Global, Companies by Type, 2016 96 Figure 67: Antibacterial Drug Market, Global, Pipeline, Overall, High-Activity and Late-Stage Developers by Level of Specialization, 2016 97 Figure 68: Antibacterial Drug Market, Global, Proportion of Total Company Revenue Attributed to Antibacterial Disease, 2015–2022 98 Figure 69: Antibacterial Drugs Market, Global, Licensing Deals by Region, Value and Year, 2006–2016 100 Figure 70: Antibacterial Drug Market, Global, Licensing Deals by Indication, 2006–2016 101 Figure 71: Antibacterial Drug Market, Global, Licensing Deals by Stage of Development and Value, 2006–2016 102 Figure 72: Antibacterial Drug Market, Global, Licensing Deals by Molecule Type, Mechanism of Action and Aggregate Deal Value, 2006–2016 103 Figure 73: Antibacterial Drug Market, Global, Co-development Deals by Region, Value and Year, 2006–2016 106 Figure 74: Antibacterial Drug Market, Global, Co-development Deals by Indication and Value, 2006–2016 107 Figure 75: Antibacterial Drug Market, Global, Co-development Deals by Stage of Development and Value, 2006–2016 108 Figure 76: Antibacterial Drug Market, Global, Co-development Deals by Molecule Type, Mechanism of Action and Aggregate Deal Value, 2006–2016 109